|Articles|February 1, 2001
- Pharmaceutical Executive-12-01-2001
- Volume 0
- Issue 0
Generics Debate Escalates
Calls for change reflect that generic products are a therapeutic mainstay and that patients and providers want earlier access to inexpensive medicines.
Advertisement
Articles in this issue
almost 24 years ago
States Target DTC Advertisingalmost 24 years ago
Transparent Momentalmost 24 years ago
IFPMA Disputes Doctors Without Boarders Reportalmost 24 years ago
GSK at Odds with Activistsalmost 24 years ago
Protecting People Everywherealmost 24 years ago
Opening the Door to Japanalmost 24 years ago
Trade Pact Weakens Patent Protectionsalmost 24 years ago
EC Questions Dual Pricingalmost 24 years ago
Genetic Test Results Off Limits-For Nowalmost 24 years ago
Precious PlasmaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
From Advantage to Essential: How Daily Data & AI Alerts Transform Commercial Functions
5
